v3.26.1
Segment Information - Summary of Financial Information for the Company's Segments (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting        
Consolidated revenue $ 161,282 $ 119,802 $ 308,723 $ 224,208
Total segment depreciation expense 1,122 1,032 2,023 2,042
Total segment amortization 716 773 1,431 1,547
Selling, general and administrative expense 29,943 26,907 58,155  
Non-segment depreciation and amortization 1,838 1,805 3,454 3,589
Loss from operations (4,616) (11,211) (11,129) (21,122)
Interest expense, net 1,859 1,870 3,793 7,440
Change in fair value of derivative warrant liabilities (6) 53 (174) 96
Change in fair value of conversion option derivative liabilities 3,243 3,987 (1,753) 7,296
Other, net 77 19 (714) 771
Consolidated loss before provision for income taxes (9,789) (17,140) (12,281) (36,725)
Operating segments        
Segment Reporting        
Consolidated revenue 161,282 119,802 308,723 224,208
Total segment direct costs 134,117 102,301 258,243 189,458
Total segment depreciation expense 819 771 1,559 1,560
Total segment amortization 716 773 1,431 1,547
Total segment operating income 25,630 15,957 47,490 31,643
Operating segments | Intravenous (IV) drug costs        
Segment Reporting        
Total segment direct costs 28,965 32,800 58,732 64,213
Operating segments | Clinician salaries and benefits        
Segment Reporting        
Total segment direct costs 16,431 14,011 31,769 28,085
Operating segments | Network medical expense        
Segment Reporting        
Total segment direct costs 9,497 1,783 16,107 1,783
Operating segments | Medical supplies and other        
Segment Reporting        
Total segment direct costs 1,878 2,556 3,546 4,149
Items not allocated to segments        
Segment Reporting        
Selling, general and administrative expense 29,943 26,907 58,155 52,283
Non-segment depreciation and amortization 303 261 464 482
Patient services | Operating segments        
Segment Reporting        
Consolidated revenue 58,827 55,891 117,914 108,959
Total segment direct costs 56,771 51,150 110,154 98,230
Total segment depreciation expense 816 767 1,553 1,522
Total segment amortization 716 718 1,431 1,437
Total segment operating income 524 3,256 4,776 7,770
Specialty pharmacy | Operating segments        
Segment Reporting        
Consolidated revenue 98,608 62,573 186,149 111,866
Total segment direct costs 77,346 51,086 148,089 90,949
Total segment depreciation expense 3 4 6 6
Total segment operating income 21,259 11,483 38,054 20,911
Clinical trials & other | Operating segments        
Segment Reporting        
Consolidated revenue 3,847 1,338 4,660 3,383
Total segment direct costs 0 65 0 279
Total segment depreciation expense 0 0 0 32
Total segment amortization 0 55 0 110
Total segment operating income $ 3,847 $ 1,218 $ 4,660 $ 2,962